Tumour-associated macrophages are an essential component of the tumour
microenvironment and have a role in the orchestration of angiogenesis, extracellular matrix …

Immunotherapy has made remarkable strides in cancer therapy over the past decade.
However, such emerging therapy still suffers from the low response rates and immune …

Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Cancer immunotherapies, such as immune checkpoint blockade and chimeric antigen
receptor (CAR) T cell therapy, have transformed clinical oncology. However, limited patient …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Although more than a decade has passed since the approval of immune checkpoint
inhibitors (ICIs) for the treatment of melanoma and non-small-cell lung, breast and …

Despite the revolutionary impact of immune checkpoint blockade (ICB) in cancer treatment,
accurately predicting patient responses remains challenging. Here, we analyzed a large …